

Management Team

Dr. Eric Leire, MD, MBA
Chief Executive Officer

Bertrand Alexandre
Chief Operating Officer

Dr. Eric Verdin
Head of Buck Institute
Chair of Scientific Advisory Board

Dr. Matthew Hirshey
Duke University
Scientific Advisory Board

Dr. Manlio Vinciguerra
P.I. at ICRC
Scientific Advisory Board

Dr. Aubrey de Grey
Sens Foundation
Scientific Advisory Board

Dr. Vera Gorbunova
University of Rochester NY
Scientific Advisory Board

Andrew Scott
London School of Economics
Board Member

Contact

Eric Leire, Founder & CEO

eric@genflowbio.com

www.genflowbio.com

GenFlow Biosciences
Biopark Gosselies

Belgium

Tax ID : BE.0753.904.685



Private biotech company with the audacious mission to deliver medicines that potentially halt, slow or reverse the aging process in dogs and humans

Lead Compound: GF-1002: Episomal transient centenarian SIRT6 gene delivery to extend lifespan and increase health span

Ten reasons to own GenFlow Biosciences

1. 'Big bang for a small buck': Genflow currently appears undervalued against a range of comparable longevity companies.
2. We assume that GenFlow can be re-rated by the market as the quality of the science behind GF-1002 becomes apparent, and as GF-1002 moves into clinical trials. The company is on track to a listing on OTCQB in 2022.
3. GenFlow's approach is backed up by a solid scientific literature on the role of SIRT6 gene in aging process.
4. Recent progress in gene delivery technology allows safe and cost effective delivery of centenarian SIRT6 gene
5. A risk minimizing approach drives our development strategy (veterinary opportunity).
6. Genflow adopts a fast-to-market strategy: we aim to achieve proof of concept rapidly and at a low cost while positioning successful projects for 'pharma-quality' late-stage development
7. Proprietary technology with patent pending.
8. Large unmet need: ageing population.
9. Well-managed company by a seasoned team with a low fixed cost structure.
10. With success, the upside could be enormous.